Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Microba Life Sciences (ASX: MAP) is a precision microbiome science company dedicated to advancing human health through groundbreaking analysis of the gut microbiome. Leveraging world-leading technology, Microba offers comprehensive gut microbiome testing services for consumers, clinicians, and researchers. The company also engages in the discovery and development of novel therapeutics derived from the human gut microbiome, targeting chronic diseases. Microba's data-driven approach aims to unlock the complex connections between the microbiome and health, paving the way for personalized medicine and innovative treatments.
The headquarters serves as the central hub for research and development, laboratory operations, bioinformatics, product development, commercial activities, and corporate administration.
Co-located within the Translational Research Institute (TRI), a world-class biomedical research facility. This provides access to state-of-the-art laboratories, cutting-edge equipment, and a collaborative environment with leading researchers and clinicians.
Microba fosters an innovative, collaborative, and scientifically rigorous work culture. Employees are driven by a shared mission to improve human health through microbiome science, emphasizing teamwork, continuous learning, and a commitment to excellence.
The location within TRI is highly significant, facilitating direct collaboration with academic and clinical partners, accelerating research translation, and positioning Microba at the forefront of microbiome innovation.
Microba supports global pharmaceutical companies in drug discovery and development programs through its advanced microbiome analysis and data insights. Its testing services are available to consumers and clinicians in Australia, New Zealand, the United Kingdom, and selected other European countries. In the United States, testing and research services are facilitated through its subsidiary Microba Inc. and strategic partnerships with major diagnostic providers like Quest Diagnostics and Genova Diagnostics.
Translational Research Institute (TRI), 37 Kent Street
Woolloongabba
QLD
Australia
Address: Not publicly specified (US-based subsidiary operations)
To facilitate and expand Microba's research services, clinical trial support, and commercial partnerships within the United States, a key market for microbiome research and therapeutic development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Microba Life Sciences' leadership includes:
Microba Life Sciences has been backed by several prominent investors over the years, including:
In the past 12-15 months, Microba has strengthened its scientific leadership with a key appointment. The executive team has otherwise demonstrated stability with no major departures reported.
Discover the tools Microba Life Sciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Microba commonly uses the [firstname].[lastname]@microba.com email format for its employees. Other general contact emails include info@microba.com for general inquiries, media@microba.com for media relations, and investors@microba.com for investor relations.
[firstname].[lastname]@microba.com
Format
jane.doe@microba.com
Example
95%
Success rate
Business Wire • May 1, 2024
Microba Life Sciences and Ginkgo Bioworks have partnered to identify novelষেLive Bacterial Therapeutics (LBTs) for autoimmune diseases by leveraging Microba's human-first, data-driven therapeutic discovery platform and Ginkgo's horizontal cell programming platform....more
Microba News / ASX • April 29, 2024
Microba announced positive preclinical results for its MAP317 Inflammatory Bowel Disease (IBD) therapeutic program, showing significant disease-modifying effects and potential for a first-in-class treatment....more
Microba News / ASX • February 27, 2024
Microba reported strong financial results for the first half of FY24, with significant revenue growth from its microbiome testing services and advancements in its therapeutic development programs, including a partnership with Pfizer....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Microba Life Sciences, are just a search away.